急性心不全における閉塞を緩和するための薬学的選択肢
Chris J Kapelios1,2, Ali Vazir3,4, Lars H Lund5
1Heart Failure Unit, Department of Cardiology, University Hospital Attikon, National and Kapodistrian University of Athens School of Medicine, Rimini 1, 12462, Haidari, Athens, Greece. chriskapel@hotmail.com.
Heart failure reviews
|August 30, 2025
まとめ
急性心不全 (AHF) の閉塞の治療には,特製の静脈循環性利尿薬,シアジドやアセタゾラミドなどの選択肢が適用されます. 早期にSGLT2阻害剤とスピロノラクトンを投与することを推奨し,クレアチニン値の変化は治療の停止を正当化しません.
科学分野:
- 心臓病科
- 薬理学について
- 腎臓科
背景:
- 大抵の急性心不全 (AHF) の入院の主な懸念事項は,閉塞です.
- AHFの混雑に対する薬理学的な戦略は,広範な研究が欠け,臨床的実践と結果が異なっています.
研究 の 目的:
- AHFで入院した患者の混雑管理のための証拠に基づいた勧告を提供すること.
- AHFの解凍における様々な薬理学的作用とモニタリングパラメータを明確にする.
主な方法:
- AHFに対する尿薬反応と薬理学的介入に関する現在の証拠のレビュー.
- 解凍治療の推奨されたタイミングと用量戦略の分析
- AHF治療中の腎機能マーカーの解釈に関するガイドライン
主要な成果:
- 初期治療は静脈注入のループ利尿薬で,初期利尿薬反応 (尿中のナトリウム/出荷量) に基づいて投与量を調整します.
- 低最適の反応は,ループの利尿剤の投与量を増加させ,シアジドまたはアセタゾラミドを追加することを示唆する.
- すべてのAHF患者では,ナトリウム・グルコース・コトランスポーター-2阻害剤とスピロノラクトンを早期に投与する必要があります.
- 血清クレアチニンの一時的な上昇は,本当の腎機能不全を示さないため,治療を中止すべきではありません.
結論:
- AHFの減圧を最適化するには,段階的な,証拠に基づいた薬理学的アプローチが必要です.
- SGLT2阻害剤とスピロノラクトンの早期かつ適切な使用は極めて重要です.
- 臨床医は,AHFの解凍の文脈で,クレアチニンの変化のみに基づいた治療の緩和に注意する必要があります.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717